Publications
Partners
It is the sixth HIV drug to be tested by the International Partnership for Microbicides, said the group's chief executive officer, Dr Zeda Rosenberg.
The drug is known only by its experimental name L'644. It is a member of a class of drugs known as gp41 fusion inhibitors. They stop the Aids virus from attaching to the immune system cells it targets.
"It's a completely different mechanism of action to what we have currently under development and what the field has under development," Rosenberg told Reuters in a telephone interview.
"It's pretty early in the life cycle for HIV. Most of us feel that, for a microbicide to be really effective, it has to get at the infection in its earliest time points."
Microbicides are products, such as gels or creams, that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes Aids.
So far, attempts to create a microbicide have failed.
The Aids virus has infected 33 million people globally, according to the World Health Organization. It has killed 25 million, and there is no vaccine to prevent the fatal and incurable virus.
Many refuse to use condoms
Condoms can protect men and women, but health experts note that many men refuse to use them. In many countries, a woman who demands that her husband or partner use a condom can face refusal or even a beating.
According to the United Nations, in sub-Saharan Africa almost 61 percent of adults infected with HIV are women. Most cases of HIV are transmitted sexually.
The nonprofit IPM has another agreement with Merck for a royalty-free license to develop another compound, L'167/CMPD167, which belongs to the class of molecules known as CCR5 blockers.
"Merck is pleased to contribute the results of our research and development to this worldwide effort to protect women from HIV infection," said Dr Daria Hazuda, vice president of scientific affairs for infectious disease and HIV at Merck Research Laboratories.
The microbicides group also has agreements with Pfizer to develop its CCR5 blocker maraviroc; with Gilead Sciences to develop tenofovir, a licensed HIV drug; with Bristol-Myers Squibb; and with Johnson & Johnson subsidiary Tibotec Pharmaceuticals to try to make a microbicide out of its HIV drug dapivirine.
The field could use some successes.
Last month a study showed one microbicide candidate, called Carraguard, did not protect women from infection.
Two other potential microbicides have made women more likely to become infected - a spermicide called nonoxynol-9 and a product called Ushercell, made by Toronto-based Polydex Pharmaceuticals. - (Maggie Fox/Reuters Health)
Read more:
Major Aids gel setback
HIV/Aids Centre
March 2008
